{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:59:31Z","timestamp":1788184771107,"version":"build-2803163510"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hairy cell leukemia (HCL) is an indolent leukemic B-cell malignancy that typically presents with pancytopenia and splenomegaly. Many patients achieve durable initial remissions with nucleoside analogs but ultimately relapse as leukemic cells acquire or exploit resistance mechanisms. Central to this resistance is the highly specialized leukemic microenvironment, particularly within bone marrow and splenic niches where hairy cells persist despite clearance of circulating disease. These protective niches provide CXCR4- and adhesion-dependent retention signals, cytokine support, and immune-evasion mechanisms that sustain leukemic survival, promote minimal residual disease, and ultimately drive relapse. In this Mini Review, we summarize how stromal interactions, extracellular-matrix remodeling, and disrupted immune surveillance reinforce therapeutic resistance in HCL, and how BCR and MAPK signaling interact with these circuits. Further, we highlight emerging strategies, including agents that disrupt chemotaxis, adhesion, and immune checkpoints, designed to dismantle microenvironmental support and improve the depth and durability of remission in HCL.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1728452","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:03:56Z","timestamp":1770296636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune activation and microenvironmental crosstalk in hairy cell leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Hammad","family":"Tanzeem","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Vick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati","place":["Cincinnati, OH, United States"]},{"name":"Division of Hematology\/Oncology, University of Cincinnati","place":["Cincinnati, OH, United States"]},{"name":"Division of Experimental Hematology and Cancer Biology, Cincinnati Children\u2019s Hospital Medical Center","place":["Cincinnati, OH, United States"]},{"name":"University of Cincinnati Cancer Center","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-745711","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv200","article-title":"Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Robak","year":"2015","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid Malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/cancers14041050","article-title":"Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders","volume":"14","author":"Maitre","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-020-0328-z","article-title":"Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up","volume":"10","author":"Paillassa","year":"2020","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01419-z","article-title":"Hairy cell leukemia: where are we in 2023","volume":"25","author":"Mendez-Hernandez","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18224","article-title":"Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall","volume":"198","author":"De Propris","year":"2022","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2406376","article-title":"Hairy-cell leukemia","volume":"391","author":"Falini","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-244830","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.001001","article-title":"Germinal centers","volume":"12","author":"MacLennan","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1084\/jem.20031175","article-title":"Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors","volume":"199","author":"Basso","year":"2004","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024059","article-title":"Genome-wide promoter methylation of hairy cell leukemia","volume":"3","author":"Arribas","year":"2019","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2015.10.019","article-title":"Bone marrow and splenic histology in hairy cell leukaemia","volume":"28","author":"Wotherspoon","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18060","article-title":"Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment","volume":"28","author":"Troussard","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0893","article-title":"CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy","volume":"75","author":"Poret","year":"2015","journal-title":"Cancer Res"},{"key":"B17","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41408-020-00384-1","article-title":"Hairy cell leukemia expresses programmed death-1","volume":"10","author":"Kumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2010.05.003","article-title":"Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment","volume":"37","author":"Robak","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14388","article-title":"Atypical hairy cell leukemia-the current status and future directions","volume":"114","author":"Robak","year":"2025","journal-title":"Eur J Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"020502","DOI":"10.1016\/j.beha.2015.09.006","article-title":"Hairy cell leukemia - etiopathogenesis, diagnosis and modern therapeutic approach","volume":"34","author":"Mackowiak","year":"2024","journal-title":"Biochem Med (Zagreb)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2015.09.006","article-title":"The importance of the tissue microenvironment in hairy cell leukemia","volume":"28","author":"Sivina","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1760.1760","article-title":"Adhesion of hairy cells leukemia (HCL) cells to stromal cells can be inhibited by blocking VLA-4 integrins and CXCR4 chemokine receptors","volume":"118","author":"Sivina","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02210.x","article-title":"Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia","volume":"111","author":"Chilosi","year":"2000","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627307","article-title":"Recurrent CDKN1B (p27) mutations in hairy cell leukemia","volume":"126","author":"Dietrich","year":"2015","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/cancers14030697","article-title":"The genomics of hairy cell leukaemia and splenic diffuse red pulp lymphoma","volume":"14","author":"Oscier","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-773762","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cell.2008.01.038","article-title":"Stem cells and niches: mechanisms that promote stem cell maintenance throughout life","volume":"132","author":"Morrison","year":"2008","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell Malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.02.020","article-title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological Malignancies","volume":"109","author":"Peled","year":"2018","journal-title":"Cytokine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001723449","article-title":"Chemokine receptor expression in B-cell lymphoproliferative disorders","volume":"45","author":"Wong","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V73.4.880.880","article-title":"High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia","volume":"73","author":"Lindemann","year":"1989","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.3945.bloodjournal88103945","article-title":"Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder","volume":"67","author":"Vincent","year":"1996","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/67.5.415","article-title":"Splenic pseudosinuses and hepatic angiomatous lesions. Distinctive features of hairy cell leukemia","volume":"67","author":"Nanba","year":"1977","journal-title":"Am J Clin Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature10160","article-title":"In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche","volume":"474","author":"Fujisaki","year":"2011","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V100.2.647","article-title":"Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion","volume":"100","author":"Baker","year":"2002","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1006\/cimm.1998.1318","article-title":"Interleukin-3 and Flt3-ligand induce adhesion of Baf3\/Flt3 precursor B-lymphoid cells to fibronectin via activation of VLA-4 and VLA-5","volume":"187","author":"Shibayama","year":"1998","journal-title":"Cell Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030338","article-title":"Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress","volume":"124","author":"Kandalam","year":"2011","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007353","article-title":"Phase I\/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-beta monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors","volume":"11","author":"Bauer","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-4-444","article-title":"Impaired marrow granulocyte reserve and leukocyte mobilization in leukemic reticuloendotheliosis","volume":"87","author":"Yam","year":"1977","journal-title":"Ann Intern Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hon.2900110207","article-title":"Evidence of colony suppressor activity and deficiency of hematopoietic growth factors in hairy cell leukemia","volume":"11","author":"Gasche","year":"1993","journal-title":"Hematol Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/ijms22157780","article-title":"A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia","volume":"137","author":"Salib","year":"2021","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157780","article-title":"The biology of classic hairy cell leukemia","volume":"22","author":"Bohn","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1172\/JCI19540","article-title":"TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia","volume":"113","author":"Shehata","year":"2004","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2002-12-3737","article-title":"The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL)","volume":"102","author":"Aziz","year":"2003","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.V83.2.497.497","article-title":"The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells","volume":"83","author":"Burthem","year":"1994","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V94.3.1077.415k06_1077_1085","article-title":"Basic fibroblast growth factor is expressed by CD19\/CD11c-positive cells in hairy cell leukemia","volume":"94","author":"Gruber","year":"1999","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1038\/nrc1888","article-title":"Evolving concepts in the pathogenesis of hairy-cell leukaemia","volume":"6","author":"Tiacci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04310.x","article-title":"Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts","volume":"72","author":"Kimura","year":"1989","journal-title":"Br J Haematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1798-6","article-title":"EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-beta\/Smad and ROS signaling","volume":"72","author":"Park","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01601-1","article-title":"Targeting TGF-beta signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","article-title":"CCL4 signaling in the tumor microenvironment","volume":"1231","author":"Mukaida","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12867","article-title":"The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach","volume":"166","author":"Sivina","year":"2014","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008990","article-title":"Zanubrutinib for the treatment of relapsed\/refractory hairy cell leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Blood Adv"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-11-316737","article-title":"Evidence of canonical somatic hypermutation in hairy cell leukemia","volume":"117","author":"Arons","year":"2011","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V87.9.3795.bloodjournal8793795","article-title":"Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia","volume":"87","author":"Kluin-Nelemans","year":"1996","journal-title":"Blood"},{"key":"B69","article-title":"T lymphocyte function in hairy cell leukaemia","volume":"42","author":"Sabbe","year":"1980","journal-title":"Clin Exp Immunol"},{"key":"B70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V93.1.251","article-title":"Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones","volume":"93","author":"van de Corput","year":"1999","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03318.x","article-title":"Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia","volume":"116","author":"Bourguin-Plonquet","year":"2002","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328193","article-title":"Mechanisms underlying immunosuppression by regulatory cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.146.2.492","article-title":"The role of CD11a\/CD18-CD54 interactions in human T cell-dependent B cell activation","volume":"146","author":"Tohma","year":"1991","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2010.03308.x","article-title":"T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell Malignancies","volume":"131","author":"Lindqvist","year":"2010","journal-title":"Immunology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"19056","DOI":"10.1038\/s41598-021-98536-1","article-title":"Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers","volume":"11","author":"Koldej","year":"2021","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.568649","article-title":"The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets","author":"Burger","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V80.8.2060.2060","article-title":"Interferon-\u03b1 Downregulates the abnormal intracytoplasmic free calcium concentration of tumor cells in hairy cell leukemia","volume":"80","author":"G\u00e9not","year":"1992","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V72.3.936.bloodjournal723936","article-title":"Effect of alpha-interferon therapy on bone marrow fibrosis in hairy cell leukemia","volume":"72","author":"Laughlin","year":"1988","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.04.008","article-title":"Detangling the threads of hairy cell leukemia, beyond the morphology and into the molecular","volume":"24","author":"Brazel","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients","volume":"17","author":"Maloisel","year":"2003","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"crossref","DOI":"10.3390\/biom10081140","article-title":"Development of recombinant immunotoxins for hairy cell leukemia","volume":"10","author":"Kreitman","year":"2020","journal-title":"Biomolecules"},{"key":"B85","doi-asserted-by":"crossref","DOI":"10.3343\/lmo.2019.9.4.236","volume-title":"Efficacy of annexin A1 immunostaining in bone marrow for the diagnosis of hairy cell leukemia","author":"Park","year":"2019"},{"key":"B86","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.570819","article-title":"Infectious complications in hairy cell leukemia","author":"Kraut","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2017.0165","article-title":"Hairy cell leukemia, version 2.2018, NCCN clinical practice guidelines in oncology","volume":"15","author":"Wierda","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300074","article-title":"Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia","volume":"2","author":"Park","year":"2023","journal-title":"NEJM Evid"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2013.827187","article-title":"Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)","volume":"55","author":"Lopez Rubio","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14207","article-title":"Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia","volume":"175","author":"Getta","year":"2016","journal-title":"Br J Haematol"},{"key":"B95","article-title":"New bispecific antibodies in diffuse large B-cell lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"B96","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2024.2304026","article-title":"Therapy with mosunetuzumab, a bispecific antibody for relapsed\/refractory hairy cell leukemia","volume":"65","author":"Tadmor","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168622","article-title":"T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions","volume":"13","author":"Russler-Germain","year":"2023","journal-title":"Front Oncol"},{"key":"B98","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"B99","article-title":"Complete response in hairy cell leukemia to anti-CD22 CAR T-cell therapy","volume":"9","author":"Kreitman","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1093\/intimm\/dxu096","article-title":"Therapeutic uses of anti-alpha4-integrin (anti-VLA-4) antibodies in multiple sclerosis","volume":"27","author":"Schwab","year":"2015","journal-title":"Int Immunol"},{"key":"B102","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"key":"B103","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus Rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1728452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:54:08Z","timestamp":1771926848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1728452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":104,"alternative-id":["10.3389\/fimmu.2025.1728452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1728452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1728452"}}